Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ortop (Sao Paulo) 2019; 54(05): 524-530
DOI: 10.1016/j.rbo.2018.02.002
Artigo Original | Original Article
Sociedade Brasileira de Ortopedia e Traumatologia. Published by Thieme Revnter Publicações Ltda Rio de Janeiro, Brazil

O impacto da histologia do carcinoma pulmonar na frequência das metástases ósseas[*]

Article in several languages: português | English
Marcelo Bragança dos Reis Oliveira 
1   Serviço de Traumato-Ortopedia, Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho, (HUCFF), Rio de Janeiro, RJ, Brasil
,
Larissa Costa Souza
1   Serviço de Traumato-Ortopedia, Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho, (HUCFF), Rio de Janeiro, RJ, Brasil
,
Ermides Javier Garcia Sampayo
1   Serviço de Traumato-Ortopedia, Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho, (HUCFF), Rio de Janeiro, RJ, Brasil
,
Gustavo Sobral de Carvalho
1   Serviço de Traumato-Ortopedia, Universidade Federal do Rio de Janeiro (UFRJ), Hospital Universitário Clementino Fraga Filho, (HUCFF), Rio de Janeiro, RJ, Brasil
,
Fernanda Carvalho de Queiroz Mello
2   Faculdade de Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brasil
,
Marcos Eduardo Machado Paschoal
3   Instituto de Doenças do Tórax,Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brasil
› Author Affiliations
Further Information

Publication History

12 September 2017

21 February 2018

Publication Date:
19 September 2019 (online)

   Permissions and Reprints

Resumo

Objetivo O câncer de pulmão é a principal causa de morte por neoplasia, e os ossos são os principais locais de metástases desse tipo de câncer. O objetivo deste estudo foi avaliar a influência do tipo histológico do carcinoma de pulmão na frequência das metástases ósseas.

Métodos Foram avaliados retrospectivamente os registros médicos de 407 pacientes diagnosticados com câncer de pulmão entre 2003 e 2012. A prevalência de metástases ósseas e suas associações com os subtipos histológicos foram avaliadas com o teste qui-quadrado, razão de probabilidade (RP), e intervalos de confiança (IC) de 95%. A sobrevida global foi avaliada com o método de Kaplan-Meier.

Resultados A prevalência das metástases ósseas foi de 28,2% (n = 115), e a coluna vertebral foi o local mais frequente (98 metástases: 32,1%). O adenocarcinoma foi o subtipo histológico mais comum de carcinoma pulmonar (46,7%) e foi significativamente mais frequente entre os pacientes com metástases ósseas (13,0% versus 29,8%; p = 0,0004; OR = 0,35; 95% IC: 0,19–0,64). O tempo médio de sobrevida após o diagnóstico da primeira metástase óssea foi de 4 meses.

Conclusão O adenocarcinoma foi o subtipo histológico mais comum de carcinoma pulmonar e foi significativamente associado a um maior risco de desenvolvimento de metástases ósseas.

Palavras-chave

neoplasias pulmonares - metástase neoplásica - histologia

* Trabalho feito no Serviço de Traumato-Ortopedia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil. Publicado Originalmente por Elsevier Ltda.


 

  • Referências

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (01) 5-29
    CrossrefPubMedGoogle Scholar
  • 2 Malta DC, Moura L, Souza MF, Curado MP, Alencar AP, Alencar GP. Tendência de mortalidade do câncer de pulmão, traquéia e brônquios no Brasil, 1980–2003. J Bras Pneumol 2007; 33 (05) 536-543
    CrossrefPubMedGoogle Scholar
  • 3 Novaes FT, Cataneo DC, Ruiz Junior RL, Defaveri J, Michelin OC, Cataneo AJM. Lung cancer: histology, staging, treatment and survival. J Bras Pneumol 2008; 34 (08) 595-600
    CrossrefPubMedGoogle Scholar
  • 4 Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 2008; 466 (03) 729-736
    CrossrefPubMedGoogle Scholar
  • 5 Katagiri H, Takahashi M, Wakai K, Sugiura H, Kataoka T, Nakanishi K. Prognostic factors and a scoring system for patients with skeletal metastasis. J Bone Joint Surg Br 2005; 87 (05) 698-703
    CrossrefPubMedGoogle Scholar
  • 6 Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 2010; 67 (01) 4-11
    CrossrefPubMedGoogle Scholar
  • 7 Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol 2013; 2 (01) 22-29
    CrossrefPubMedGoogle Scholar
  • 8 Avelino CU, Cardoso RM, Aguiar SS, Silva MJ. Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel. J Bras Pneumol 2015; 41 (02) 133-142
    CrossrefPubMedGoogle Scholar
  • 9 Sun JM, Ahn JS, Lee S. , et al. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 2011; 71 (01) 89-93
    CrossrefPubMedGoogle Scholar
  • 10 Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57 (02) 229-232
    CrossrefPubMedGoogle Scholar
  • 11 Cetin K, Christiansen CF, Jacobsen JB, Nørgaard M, Sørensen HT. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer 2014; 86 (02) 247-254
    CrossrefPubMedGoogle Scholar
  • 12 Lorusso V, Duran I, Garzon-Rodriguez C. , et al. Health resource utilisation associated with skeletal-related events in European patients with lung cancer: a subgroup analysis from a prospective multinational study. Mol Clin Oncol 2014; 2 (05) 701-708
    CrossrefPubMedGoogle Scholar
  • 13 Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. Int J Clin Pract 2003; 57 (03) 184-186
    PubMedGoogle Scholar
  • 14 Oliveira MB, Mello FC, Paschoal ME. The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases. Lung Cancer 2016; 96 (01) 19-24
    CrossrefPubMedGoogle Scholar
  • 15 Travis WD, Brambilla E, Noguchi M. , et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6 (02) 244-285
    CrossrefPubMedGoogle Scholar
  • 16 Lee DS, Kang JH, Lee CG. , et al. Predicting survival in patients with advanced non-squamous non-small cell lung cancer: validating the extent of metastasis. Cancer Res Treat 2013; 45 (02) 95-102
    CrossrefPubMedGoogle Scholar
  • 17 Yu JL, Simmons C, Victor JC. , et al. Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer. Oncologist 2011; 16 (09) 1307-1315
    CrossrefPubMedGoogle Scholar
  • 18 Quint LE, Tummala S, Brisson LJ. , et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996; 62 (01) 246-250
    CrossrefPubMedGoogle Scholar
  • 19 Salvatierra A, Baamonde C, Llamas JM, Cruz F, Lopez-Pujol J. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97 (05) 1052-1058
    CrossrefPubMedGoogle Scholar
  • 20 Michel F, Solèr M, Imhof E, Perruchoud AP. Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning. Thorax 1991; 46 (07) 469-473
    CrossrefPubMedGoogle Scholar
  • 21 Tornyos K, Garcia O, Karr B, LeBeaud R. A correlation study of bone scanning with clinical and laboratory findings in the staging of nonsmall-cell lung cancer. Clin Nucl Med 1991; 16 (02) 107-109
    CrossrefPubMedGoogle Scholar
  • 22 Kosteva J, Langer C. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 2004; 46 (Suppl. 01) S45
    Google Scholar
  • 23 Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T. Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy. Lung Cancer 2009; 65 (02) 219-222
    CrossrefPubMedGoogle Scholar
  • 24 Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003; 41 (03) 245-258
    CrossrefPubMedGoogle Scholar
  • 25 Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997; 26 (01) 14-23
    CrossrefPubMedGoogle Scholar
  • 26 Westphal FL, Lima LC, Andrade EC, Lima Netto JC, Silva AS, Carvalho BC. Características de pacientes com câncer de pulmão na cidade de Manaus. J Bras Pneumol 2009; 35 (02) 157-163
    CrossrefPubMedGoogle Scholar
  • 27 Heidemann F, Schildt A, Schmid K. , et al. Selectins mediate small cell lung cancer systemic metastasis. PLoS One 2014; 9 (04) e92327
    CrossrefPubMedGoogle Scholar
  • 28 Sathiakumar N, Delzell E, Morrisey MA. , et al. Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006. Lung India 2013; 30 (01) 20-26
    CrossrefPubMedGoogle Scholar
  • 29 Bae HM, Lee SH, Kim TM. , et al. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 2012; 77 (03) 572-577
    CrossrefPubMedGoogle Scholar
  • 30 Hansen BH, Keller J, Laitinen M. , et al. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl 2004; 75 (311) 11-15
    CrossrefPubMedGoogle Scholar